BioMarin Pharmaceuticals, Inc. (BMRN)

Company Description

BioMarin develops and commercializes innovative biopharmaceuticals for serious diseases and medical conditions. The company’s product portfolio comprises four approved products and multiple clinical and pre-clinical product candidates. Approved products include Naglazyme(R) (galsulfase) for mucopolysaccharidosis VI (MPS VI), a product wholly developed and commercialized by BioMarin; Aldurazyme(R) (laronidase) for mucopolysaccharidosis I (MPS I), a product which BioMarin developed through a 50/50 joint venture with Genzyme Corporation; Kuvan(R) (sapropterin dihydrochloride) Tablets, for phenylketonuria (PKU), developed in partnership with Merck Serono, a division of Merck KGaA of Darmstadt, Germany; and Firdapse(TM) (amifampridine), which has been approved by the European Commission for the treatment of Lambert Eaton Myasthenic Syndrome (LEMS). Product candidates include BMN-110 (N-acetylgalactosamine 6-sulfatase), formally referred to as GALNS, which successfully completed Phase III clinical development for the treatment of MPS IVA, PEG-PAL (PEGylated recombinant phenylalanine ammonia lyase), which is currently in Phase II clinical development for the treatment of PKU, BMN-701, a novel fusion protein of insulin-like growth factor 2 and acid alpha glucosidase (IGF2-GAA), which is currently in Phase I/II clinical development for the treatment of Pompe disease, BMN-673, a poly ADP-ribose polymerase (PARP) inhibitor, which is currently in Phase I/II clinical development for the treatment of genetically-defined cancers, and BMN-111, a modified C-natriuretic peptide, which is currently in Phase I clinical development for the treatment of achondroplasia.

COMPANY ADDRESS
105 Digital Drive
Novato, CA 94949
United States

COMPANY PHONE
415-506-6700

COMPANY WEBSITE



Get BioInvest's perspective on BioMarin's CEO


Latest Company News

Knuckling Down on Shares of BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) and ... FLBC News - 5 hours ago Keen investors are consistently searching for true bargains in the stock market. Finding these stocks can make the difference between a winning or losing portfolio. [...]
Fri, Aug 18, 2017 11:37:00 PM, Continue reading at the source
BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) Closed -7.8% Below Its 50 Day Average Modern Readers - 17 hours ago Here is the rundown on market activity for BioMarin Pharmaceutical Inc. (NASDAQ:BMRN). EVP George Eric Davis sold 9,844 shares at an average price of $96.60 on Fri the 23rd. Is It Time to go for BioMarin Pharmaceutical Inc. (BMRN), MPLX LP (MPLX)? - StockNewsJournal Hedge Funds Now Own 100% Of BioMarin Pharmaceutical Inc. (BMRN) - Post Analyst [...]
Fri, Aug 18, 2017 11:26:00 AM, Continue reading at the source
BioMarin Pharmaceutical Inc A Clever Put Spread CML News - Aug 18, 2017 Selling puts is a common option strategy during a bull market, but it turns out that looking at a lower risk put spread, and being rather clever in how we treat earnings, yields powerful results in BioMarin Pharmaceutical Inc (NASDAQ:BMRN) . More ... [...]
Fri, Aug 18, 2017 1:07:00 AM, Continue reading at the source
BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) Closed Much Lower Than Its 50 Day ... Modern Readers - Aug 10, 2017 Here is the rundown on market activity for BioMarin Pharmaceutical Inc. (NASDAQ:BMRN). EVP George Eric Davis disclosed the sale of 9,844 shares of BMRN stock. 2 Stocks to keep an eye on Today: BioMarin Pharmaceutical Inc. (BMRN ... - StockNewsJournal Traders Take Note: BioMarin Pharmaceutical Inc (NASDAQ:BMRN) Stock Drops ... - CML News [...]
Thu, Aug 10, 2017 5:32:00 PM, Continue reading at the source
BioMarin prices $450M convertible debt offering Seeking Alpha - Aug 7, 2017 Underwriters have a 13-day option to buy up to an addition $45M worth. The company will use most of the net proceeds to settle some or all of its 0.75% senior subordinated convertible notes due October 2018. [...]
Mon, Aug 07, 2017 11:48:00 PM, Continue reading at the source
BioMarin Announces Offering of $450 Million of Senior Subordinated Convertible ... PR Newswire (press release) - Aug 7, 2017 7, 2017 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN), announced today an underwritten offering of $450 million aggregate principal amount of senior subordinated convertible notes due 2024 (the Notes). [...]
Mon, Aug 07, 2017 8:04:00 PM, Continue reading at the source
BioMarin Pharmaceutical results: The raw numbers Motley Fool - Aug 4, 2017 In July, BioMarin presented promising data for BMN 270, a gene therapy treatment for hemophilia A. As part of the earnings report, the company reported further data on the mid-range dose, which doesn't have as much protein expression to compensate for ... [...]
Fri, Aug 04, 2017 5:37:00 PM, Continue reading at the source
BioMarin Pharmaceutical (BMRN) Q2 2017 Results - Earnings Call Transcript Seeking Alpha - Aug 3, 2017 To remind you this non-confidential presentation contains forward-looking statements about the business prospects of BioMarin Pharmaceutical Inc., including expectations regarding BioMarin's financial performance, commercial products and potential ... BioMarin Pharmaceutical Inc. (BMRN) PT Raised to $119 at Deutsche Bank - StreetInsider.com BioMarin (BMRN) Q2 Loss Narrows, Sales Surpass Estimates - Nasdaq [...]
Thu, Aug 03, 2017 4:34:00 AM, Continue reading at the source
BioMarin Announces Second Quarter 2017 Financial Results PR Newswire (press release) - Aug 2, 2017 BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced financial results for the second quarter ended June 30, 2017. For the quarter ended June 30, 2017, GAAP net loss was $36.8 million, or $0.21 per basic and diluted share, compared to GAAP ... [...]
Wed, Aug 02, 2017 8:03:00 PM, Continue reading at the source
BioMarin to Host Second Quarter 2017 Financial Results Conference Call and ... PR Newswire (press release) - Jul 31, 2017 SAN RAFAEL, Calif., July 31, 2017 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced that Jean-Jacques Bienaimé, Chairman and Chief Executive Officer of BioMarin, will host a conference call and webcast on Wednesday, ... [...]
Mon, Jul 31, 2017 7:52:00 PM, Continue reading at the source